[New approaches to antioxidant therapy in multiple sclerosis].
For study of antioxidant therapy efficiency in relapsing-remitting multiple sclerosis we investigated group 1 (18 patients) treated with alpha-lipoic acid and group 2 (14 patients) who received complex of antioxidants and neuroprotectors with various mechanisms of action (oc-lipoic acid, Nicotinamide, Acetylcysteine, Triovit Beta-carotine, Alpha-tocopheryl acetate, Ascorbic acid, Selenium, Pentoxifylline, Cerebrolysin, Amantadine hydrochloride) during 1 month, 2 times a year. The treatment resulted in significant reduction (2-3 times) of relapse frequency in multiple sclerosis patients (especially in group 2) and decrease of required corticosteroid courses. After antioxidant therapy the content of lipid peroxide products was significantly reduced (most expressed in group 2). The improved method of multicomponent antioxidant and neuroprotective therapy can be considered as pathogenic threatment in relapsing-remitting multiple sclerosis.
Odinak
M M
MM
Bisaga
G N
GN
Zarubina
I V
IV
D000328:Adult; D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005978:Glutathione / Q000378:metabolism; D005980:Glutathione Reductase / Q000378:metabolism; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D009249:NADP / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism
D000975:Antioxidants; D008315:Malondialdehyde; D009249:NADP; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D005978:Glutathione